The ratio of plasma pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosis

Authors

Sylvain Lehmann[1], Audrey Gabelle[2], Marie Duchiron[1], Germain Busto[2], Mehdi Morchikh[1], Constance Delaby[1,3], Christophe Hirtz[1], Etienne Mondesert[1,4], Jean-Paul Cristol[4], Genevieve Barnier-Figue[5], Florence Perrein[6], Cédric Turpinat[2], Snejana Jurici[5], Karim Bennys[2] for the Alzheimer's Disease Neuroimaging Initiative (ADNI) *

Affiliations

[1] LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France

[2] Université de Montpellier, Memory Research and Resources center, department of Neurology, Inserm INM, F-34000 Montpellier, France.

[3] Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain

[4] CHU de Montpellier, Hôpital Lapeyronie, Biochimie, Montpellier, France,

[5] CH Perpignan, Gériatrie, Perpignan, France,

[6] CHU de Nîmes, Neurology, Nîmes, France

Corresponding author

Pr Sylvain Lehmann, CHU and University of Montpellier, 80 av Fliche, 34295 Montpellier, France, email: sylvain.lehmann@umontpellier.fr, Tel: +33 (0)4 67 33 71 24

Word count: 3434

* Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: at:http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Abstract

IMPORTANCE. Early detection of brain amyloidosis (Aβ+) is pivotal for diagnosing Alzheimer's disease (AD) and optimizing patient management, especially in light of emerging treatments. While plasma biomarkers are promising, their combined diagnostic value through specific ratios remains underexplored.

OBJECTIVE. To evaluate the diagnostic accuracy of plasma pTau isoform (pTau181 and pTau217) to Aβ42 ratios in detecting Aβ+ status.

DESIGN, SETTING, AND PARTICIPANTS. This study included 423 participants from the multicenter prospective ALZAN cohort, recruited for cognitive complaints. Aβ+ status was determined using cerebrospinal fluid (CSF) biomarkers. Validation of the key findings was performed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, where Aβ+ status was determined using PET imaging.

EXPOSURES. Plasma biomarkers (pTau181, pTau217, Aβ40, Aβ42) were measured using immunoassays and mass spectrometry, with specific ratios calculated. In the ALZAN cohort, the impact of confounding factors such as age, renal function, ApoE4 status, body mass index, and the delay between blood collection and processing was also evaluated to assess their influence on biomarker concentrations and diagnostic performance.

MAIN OUTCOMES AND MEASURES. The primary outcome was the diagnostic performance of plasma biomarkers and their ratios for detecting Aβ+ status. Secondary outcomes included the proportion of patients classified as low, intermediate, or high risk for Aβ+ using a two-cutoff approach.

RESULTS. The pTau181/Aβ42 ratio matched the diagnostic performance of pTau217 with AUC of 0.911 (0.880-0.936). The pTau217/Aβ42 ratio demonstrated the highest diagnostic accuracy in the ALZAN cohort, with an AUC of 0.927 (0.898-0.950), outperforming

individual biomarkers. Both ratios effectively mitigated confounding factors, such as variations in renal function, and were particularly excellent in identifying Aβ+ status in individuals with early cognitive decline. Validation in the ADNI cohort confirmed these findings, with consistent performance across different measurement methods. The two-cutoff workflow using pTau217/Aβ42 reduced the intermediate-risk zone from 16% to 8%, enhancing stratification for clinical decision-making.

CONCLUSIONS AND RELEVANCE. The pTau217/Aβ42 ratio offers superior diagnostic accuracy for detecting Aβ+ compared to individual biomarkers and reduces diagnostic uncertainty. These findings highlight the clinical utility of plasma biomarker ratios for early AD detection, paving the way for broader implementation in clinical and research settings.

Introduction

Over the past decade, the contribution of imaging and cerebrospinal fluid (CSF) biomarkers has provided essential elements for the diagnosis of Alzheimer's disease (AD) [1]. These biomarkers significantly enhance diagnostic confidence when combined with clinical and paraclinical information [2]. CSF biomarkers are part of the international diagnostic criteria for the disease [3, 4, 5, 6], enabling more accurate and earlier diagnoses. This is particularly critical for optimizing patient management, especially in the light of emerging treatments, such as anti-amyloid immunotherapies [7, 8].

In north America, cerebral amyloidosis is often detected by amyloid PET imaging [9], whereas in Europe, cerebrospinal fluid (CSF) biomarkers, are used to confirm the presence of brain amyloidosis [10], a hallmark of AD pathology. CSF analysis provides further insights by also measuring the tauopathy component of the disease [11]. Furthermore, longitudinal studies have established that these biomarkers become positive up to one or two decades before disease onset, during presymptomatic phases [12]. However, Both PET imaging and CSF analysis have limitations: availability, equipment, scalability and associated costs, especially for PET, and the invasive nature of lumbar puncture for CSF. These constraints hinder their widespread application, even though the targeted treatments necessitate testing a broader population to evaluate the presence of brain amyloidosis prior to initiating treatment.

The idea of detecting amyloidosis through blood analysis has gained traction in recent years, achieving a level of development and validation that is sufficient for routine clinical application. Early research efforts primarily focused on the detection of amyloid peptides (Aβ) [13]. Detecting Aβ42 and Aβ40 in blood is accurate at around 80% for identifying a positive brain amyloidosis status, called Aβ+ [14]. Total tau protein in blood performs poorly, likely due to its peripheral production [15]. However, phosphorylated forms of tau protein

(pTau) perform much better [16]. Notably, plasma pTau181, demonstrated an accuracy for Aβ+ of around 80%, close to that of the plasma Aβ42/40 ratio. Following the detection with mass spectrometry of additional pTau isoforms [17, 18, 19]; pTau217 emerged as the biomarker with even higher accuracy for Aβ+, reaching values as high as 90-95% in different studies [20, 21, 22, 23, 24]. It might seem counterintuitive for a tau isoform to indicate amyloidosis and the exact pathophysiological mechanisms behind this observation remain incompletely understood. Nonetheless, the performance of plasma pTau217 is sufficiently powerful to confirm individuals as Aβ+ and contribute to the diagnosis of AD.

A very attractive approach has been recently described, called the 'two-step' workflow [25]. Interestingly, it corresponds to the application of a two-threshold rather than a true two-step approach. Indeed, it is possible to define, within a given population, two cutoff values: one above which the probability of being Aβ+ is greater than 90 or 95%, and another below which the risk is less than 90%. The effectiveness of this approach is measured by the size of the zone between these two cutoffs, referred to as the "intermediate zone", which should be minimized. This two cutoffs approach is optimal for tailoring care pathways and even for selecting patients who could benefit from innovative treatments. Immunoassays for pTau217 are now being developed by numerous suppliers, offering highly reliable detection for Aβ+. Head-to-head comparative studies of various assays gave largely equivalent results, with mass spectrometry methods offering a slight edge in accuracy over immunoassays [16]. These performance levels are suitable for routine use, though additional studies are needed to confirm their robustness in real-world settings. In fact, it has already been established that pre-analytical conditions [26], particularly for Aβ peptides, as well as physiological factors, like renal insufficiency [24, 27, 28], or even some drug treatment [29]can influence concentrations, leading to potential false positives or negatives.

Here we comprehensively evaluate blood Aβ peptides and pTau181 or pTau217 as ratios. By conducting this investigation within the multicentric, real-life ALZAN cohort, and confirming the findings in the independent Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, we identified the pTau217/Aβ42 ratio as an exceptionally valuable single metric for Aβ+ detection, providing clinically significant high and low cutoffs.

Results

Participants and biomarker profile

The participants are part of the ALZAN cohort (NCT05427448), a study designed to prospectively and consecutively evaluate the diagnostic performance of blood biomarkers for AD. Here we concentrate on 423 participants who were recruited at three memory clinics, consulting for cognitive complains (Supplementary Table 1). The mean age at baseline was 71.1 years (SD 10.4). The sex ratio was balanced with 197 men to 226 women. 42.8% were APOE ε4 carriers, as determined by the Elecsys immunoassay [30]. The average MMSE score at recruitment was 22.9 (SD 4.6). In terms of kidney function, the mean estimated glomerular filtration rate (eGFR) was 84.6 (SD 16.1) ml/min/1.73m². The mean levels of CSF biomarkers were as follows: Aβ42/40 ratio, 0.071 (SD 0.028); total tau, 487 (SD 346) pg/mL; and pTau181, 71.2 (SD 57.2) pg/mL. Based on the CSF Aβ42/40 ratio [31], 56.7% of the population was classified as amyloid-positive (Aβ+). Regarding blood sample processing, over 50% of the patients had their blood samples processed the next day or later (Supplementary Figure 1). All plasma measurements for Aβ40, Aβ42, pTau181, and pTau217 were above their respective lower limits of quantification (Supplementary Table 2).

The ADNI cohort includes patients with varying cognitive statuses, ranging from cognitively normal individuals to those with mild cognitive impairment and AD. Participants undergo comprehensive assessments, including neuroimaging (MRI and PET scans), fluid biomarker analysis, and cognitive testing, aimed at advancing AD research. ADNI samples, measured

using different assays (see Methods), were selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to evaluate the performance of various blood biomarkers. These samples were obtained from individuals who had plasma collected within six months of undergoing an amyloid PET (florbetapir) scan.

Comparing entry characteristics of cerebral amyloidosis positive (Aβ+) and negative (Aβ-) groups

Participants were separated into Aβ- and Aβ+ groups based on CSF Aβ42/40 ratio, using a cutoff of 0.07 in ALZAN or on PET amyloid are described in Landau et al. [32]. Table 1 reports for ALZAN the demographic, clinical, and biomarker readings of the two groups. As expected, key differences include: Aβ+ participants were significantly older than Aβ- participants (74.2 (SD 7) vs. 66.9 (SD 12.6), $p < 0.0001$), and were less likely to be male (42.0% vs. 52.8%, $p = 0.0277$). As expected, the Aβ+ group had more APOE ε4 carriers (58.4% vs. 21.7%, $p < 0.0001$), and Aβ+ participants had lower MMSE scores (22.0 ± 4.6 vs. 24.5 ± 4.0, $p < 0.0001$). For blood biomarkers, in the Aβ+ group, plasma levels of Aβ42 were significantly lower (32.3 ± 7.2 pg/mL vs. 38.7 ± 8.7 pg/mL, $p < 0.0001$). Levels of pTau181 and pTau217 were significantly higher in the Aβ+ group ($p < 0.0001$). The fold difference for pTau217 was greater than for pTau181, at 3.63 and 1.84 respectively.

Table 1: Comparison of Aβ- and Aβ+ participants from the ALZAN cohort

Variable	***Aβ-*** *(n=180)*	***Aβ+*** *(n=243)*	*p-value*	*p-value $*
Age (years)	66.9 (12.6)	74.2 (7)	<0.0001	/
Men (%)	52.8%	42.0%	0.0277	/
BMI (kg/m2)	25.6 (4.3)	24.1 (4)	0.0007	0.0140
1 or 2 APOE4 alleles (%)	21.7%	58.4%	<0.0001	<0.0001
MMSE	24.5 (4)	22 (4.6)	<0.0001	<0.0001
eGFR (mL/min/1.73m2)	86 (17.5)	83.5 (14.9)	0.1046	0.0465
Blood delay (hours)	11.8 (15.2)	8.9 (14.5)	0.0495	0.3521
Aβ40 (pg/mL)	294 (59.2)	301.4 (50.2)	0.1646	0.2439
Aβ42 (pg/mL)	38.7 (8.7)	32.3 (7.2)	<0.0001	<0.0001

Aβ42/Aβ40	0.134 (0.031)	0.107 (0.017)	<0.0001	<0.0001
pTau181 (pg/mL)	0.867 (0.45)	1.592 (0.755)	<0.0001	<0.0001
pTau217 (pg/mL)	0.162 (0.237)	0.588 (0.425)	<0.0001	<0.0001
pTau181/Aβ42	2.289 (1.212)	5.156 (2.758)	<0.0001	<0.0001
pTau217/Aβ42	0.435 (0.641)	1.914 (1.472)	<0.0001	<0.0001

Values in the number s(n) of amyloid-negative (Aβ-) and -positive (Aβ+) patients. Comparison with t-student or $\chi 2$ (p-value) and linear regression adjusted for age and sex (p-value $). Percentage are given for categorical variables, mean ± standard deviation for continuous variables. Abbreviations: APOE: apolipoprotein E; BMI, body mass index; MMSE, Mini–Mental State Examination; eGFR, estimated glomerular filtration rate.

Using individual plasma biomarkers and their ratios to detect cerebral amyloidosis

We plotted ROC curves for various individual biomarkers and their ratios to evaluate their ability to detect Aβ+ status. Figure1, panels a and b, show in ALZAN the combinations of blood amyloid peptides, with pTau181 and pTau217, respectively, which are then summarised in panel c and Supplementary table 3. In terms of amyloid, Aβ42 performance where intermediate with AUC of 0.739 (0.694-0.780), but ratio, Aβ42/40 performed significantly better with an AUC of 0.840 (0.801-0.873). For pTau181 (Figure 1a), this biomarker performed slightly better than the Aβ42/40 ratio, with an AUC of 0.857 (0.820-0.889), which was further significantly improved by taking the pTau181/(Aβ42/Aβ40) ratio (AUC 0.900 (0.719-0.843)). However, the best performance for combinations of pTau181 was found for the pTau181/Aβ42 ratio. Indeed, the pTau181/Aβ42 ratio gave an impressive AUC of 0.911 (0.880-0.936).

The tendency of studies over the last five years has been to assign pTau217 superiority to p181 in detecting amyloid positivity [23, 24, 33, 34]. Consistently, the pTau217 AUC of 0.909 (0.877-0.935) was better than for pTau181 but equivalent to that of pTau181/Aβ42. With pTau217 in combination with Aβ42, the AUCs improved still further. As with pTau181 the

best pTau217 blood biomarker came from just considering the p217/Aβ42 ratio, which gave the best AUC of all in our hands of 0.927 (0.898-0.950).

Figure 1 also illustrates, in the ADNI cohort, the combinations of blood amyloid peptides with pTau217 measured using either immunoassay (panel d) or mass spectrometry (panel e), which are subsequently summarized in panel f and Supplementary Table 4. In both cases, the Aβ42/40 ratio performed better than Aβ42 alone. pTau217 achieved an AUC of 0.894 (0.875–0.911) for immunoassay detection and 0.914 (0.897–0.930) for mass spectrometry, outperforming the Aβ42/40 ratio. When pTau217 was combined with Aβ42, the AUCs improved further, with mass spectrometry showing the best performance.

Values and statistical comparisons between AUCs are provided in Supplementary Tables 3 and 4.

We also studied in ALZAN the performance of the pTau isoforms, with and without Aβ42, to detect Aβ+, when the population was stratified based on MMSE score or APOE ε4 status (supplementary Figure 2). The pTau181/Aβ42 ratio consistently outperformed pTau181 across all conditions. pTau217/Aβ42 performed better than pTau217 alone within the early AD subgroup (MMSE >25) (0.953 (0.896-0.984) vs. 0.931 (0.867-0.970)) and in APOE ε4 non-carriers (0.935 (0.896-0.962) vs 0.91 (0.867-0.943)).

Figure 1 – ROC curves of plasma biomarkers according to amyloid status assess by CSF in ALZAN a,d ADNI.



Receiver operating characteristic curve curves for Aβ+ detection in ALZAN (a-c) and ADNI (e-g) using Aβ40, Aβ42, and Aβ42/40 in combination with pTau181 (a) or pTau217 (b,e,f). The corresponding areas under curve with 95% confidence intervals are represented in (c) and (g). InADNI, biomarker were measured using either an immunoassay approche (Fuji) or with mass spectrometry (C2N).

Association of plasma pTau217 and pTau181 levels with different biomarkers and cohort characteristics

Next, we used in ALZAN linear regression to assess the association of plasma biomarkers with age, sex, body mass index (BMI), blood processing delay, and eGFR. We profiled the Aβ- population to focus on the confounding factors influencing biomarker concentration. Aβ42 was influenced by age, blood delay (delay between collection and processing in the laboratory), and eGFR, but this was resolved when using the Aβ42/40 ratio (see discussion). pTau181 on the other end was mainly affected by altered renal function. Interestingly only the ratio to Aβ42, but not to Aβ42/40, reduced this association (Supplementary table 3). For pTau217 the situation appeared different as pTau217 seems independent of all potential confounding factors, including renal function with or without ratios with Aβ42 or Aβ42/40. The impact of renal function on pTau217 is however present as demonstrated by the significant Pearson correlation coefficient calculated with eGFR (Supplementary Table 3). Moreover, this correlation remained when using the ratio with Aβ42/40 but it was no longer observed with Aβ42.

Figure 2 – Association of plasma biomarkers and their ratios with cohort characteristics



Forest plots of associations with age, sex, BMI, blood delay and eGFR, using linear regression of z-scores, for: (a) Aβ42, Aβ42/40, (b) pTau181, pTau181/(Aβ42/40) and pTau181/Aβ42, and (c) pTau217, pTau217/(Aβ42/40) and pTau217/Aβ42. Means and 95% confidence intervals (CIs) are provided. Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate.

Stratifying the population for the risk for Aβ+

Our next objective was in ALZAN to use pTau181, pTau217, or their ratios with Aβ42, to achieve 90% positive or negative predictive values for Aβ+, thus enabling a practical clinical tool where the minimum of subjects fall into the intermediate zone grey area [25]. We thus calculated data for plotting receiving operator characteristic (ROC) curves for Aβ+ detection

with sensitivity, specificity and predictive values at the different cutoffs. The corresponding positive and negative predictive value, along with their corresponding sensitivity, and specificity are in Table 3. The relationship between ROC curves is illustrated for pTau217 and pTau217/Aβ42 in Figure 3. The stratification of the population between, low, intermediate and high-risk groups using this approach is reported Table 3 and illustrated in Figure 4a. pTau217/Aβ42 shows the lowest intermediate zone at 8.3%, divides by two when compared to pTau217, and with a distribution between groups that is also statistically different (χ^2 test, P=0.0006). This gain was achieved through an increase in the low-risk group at the expense of the intermediate-risk group. Interestingly, these low-risk patients that are better classified using pTau217/Aβ42 were older, with lower eGFR and higher Aβ40 and Aβ42 (Table 4). These results were mirrored in the population with moderate cognitive decline (MMSE ≥22), which likely correspond to population who could benefit the most from anti-amyloid immunotherapy (Figure 4b), with the intermediate zone remaining small at 8.7%.

Figure 3 –Visualisation in ALZAN of the two cutoffs on the pTau217 and pTau217/Aβ42 ROC curves.



ROC curves for Aβ+ detection using pTau217 (blue) and pTau217/Aβ42 (cyan) were plotted. Respective brackets link the two cut-points used to define low and high predictive risk for Aβ+. Note that the pTau217/Aβ42 ratio's cut-points are much closer together than those for pTau217 alone. Abbreviations: ROC: receiver operating characteristic curve.

Table 3: Two cutoff approach for Aβ+ risk detection

Variable	*High cutoff*	*PPV (%)*	*Sens (%)*	*Spe (%)*	*Low cutoff*	*NPV (%)*	*Sens (%)*	*Spec (%)*	*Low risk*	*Intermediate*	*High risk*
pTau181 (pg/mL)	> 1.500	90.2	44.9	93.3	≤ 0.713	90.1	96.3	45.6	21.5%	49.9%	28.6%
pTau217 (pg/mL)	> 0.216	90.0	84.8	87.2	≤ 0.124	90.4	95.1	62.8	29.6%	16.3%	54.1%
pTau181/Aβ42	> 3.166	90.1	82.3	87.8	≤ 2.395	90.0	94.2	70.0	33.1%	14.4%	52.5%
pTau217/Aβ42	> 0.632	90.0	85.2	87.2	≤ 0.449	90.5	93.8	79.4	37.4%	8.3%	54.4%

The high-, intermediate-, and low-risk brain amyloidosis groups were defined based on cohort stratification as follows: patients with values above high cutoff, corresponding to 90% positive predictive values, are in the high-risk group; patients with values below the lower cutoff, corresponding to 90% negative predictive values, are in the low-risk group; patients not in either of these two categories are in the intermediate group. High cutoff, Low cutoff: high and low cutoffs. PPV, NPV: positive and negative predictive values. Sens and Spec: sensitivity specificity for Aβ+.

Figure 4 – Distribution of the ALZAN population between high-, intermediate-, and low-risk brain amyloidosis groups



(a) Histograms of the ALZAN population, distributed among high-, intermediate-, and low-risk brain amyloidosis groups, are shown as defined by the cut points of pTau181, pTau217, pTau181/Aβ42, and pTau217/Aβ42 (see Table 3). The % of the population in each subgroup is indicated on the graph. (b) similar histograms in the ALZAN population with MMSE ≥22.

Table 4: Comparison in ALZAN of low risk patients detected using pTau217 and/or pTau217/Aβ42

Variable	***pTau217 and pTau217/ Aβ42*** *(n=122)*	***Only pTau217/Aβ42*** *(n=36)*	*p-value*	*p-value $*
Age (years)	64.7 (13.1)	75.2 (6.5)	<0.0001	/
Men (%)	50.8%	55.6%	0.6199	/
BMI (kg/m2)	25.8 (4.4)	26.8 (4.5)	0.2803	0.0603
1 or 2 APOE4 alleles (%)	16.4%	27.8%	0.1275	0.0829
MMSE	25.3 (3.6)	24 (4.7)	0.1223	0.3925
eGFR (mL/min/1.73m2)	89.8 (15.8)	74.1 (18.9)	<0.0001	0.0086
Blood delay (hours)	13.5 (16.8)	6.5 (8.6)	0.0182	0.1329
Aβ40 (pg/mL)	277 (49.4)	344.4 (59.5)	<0.0001	<0.0001
Aβ42 (pg/mL)	37.2 (7.7)	44.4 (11)	<0.0001	0.0016
Aβ42/Aβ40	0.136 (0.033)	0.128 (0.017)	0.1612	0.1235
pTau181 (pg/mL)	0.679 (0.222)	1.041 (0.294)	<0.0001	<0.0001
pTau217 (pg/mL)	0.078 (0.025)	0.154 (0.025)	<0.0001	<0.0001
pTau181/Aβ42	1.86 (0.553)	2.385 (0.586)	<0.0001	<0.0001
pTau217/Aβ42	0.217 (0.077)	0.36 (0.071)	<0.0001	<0.0001

Values in the number (n) of low-risk patients detected using pTau217 and/or pTau217/Aβ42. Comparison with T-student or $\chi 2$ (p-value) and linear regression adjusted for age and sex (p-value $). Percentage were used to describe categorical variables. mean ± standard deviation for continuous variables. Abbreviations: APOE: apolipoprotein E; BMI, body mass index; MMSE, Mini–Mental State Examination; eGFR, estimated glomerular filtration rate.

Discussion

The data presented here come mainly from the multicentric prospective ALZAN cohort of patients consulting at memory clinics. Our study demonstrates that plasma biomarker ratios, and particularly plasma pTau217/Aβ42, can identify early AD in clinical practice. Using high and low cutoffs for this single ratio parameter in a two-step workflow approach reduces the zone of uncertainty by more than half compared to individual phosphorylated tau isoforms. This finding is highly significant for optimizing the clinical workflow, particularly in selecting patients for anti-amyloid treatment.

We compared in ALZAN the ability of plasma biomarkers to detect brain amyloidosis (Aβ+), as defined by the CSF Aβ42/40 ratio. CSF-based amyloid status determination is considered

the gold standard in Europe due to the limited use of PET imaging. The concordance between amyloid PET imaging and CSF analyses has been well established and validated [10]. We observed performance (AUC values) for Aβ+ detection using pTau181, pTau217, and Aβ42 that are comparable to those reported in the literature [14, 16]. The use of ratios is not novel, as exemplified by the CSF and blood Aβ42/40 ratio, which consistently demonstrates superior performance over Aβ42 alone [35]. CSF Aβ42/40 reduces false negative/positive since it has the ability to account for Aβ42 levels variation not linked to the amyloid pathology but rather to preanalytical variations (tube type, preservation conditions) or physiological differences [36, 37, 38]. In addition, the fact that CSF Aβ40 levels is increased in AD [11, 39] further enhances the ratio's diagnostic performance. In blood, the Aβ42/40 ratio additionally mitigates confounding factor such as renal dysfunction, an observation that we initially made in the BALTAZAR MCI cohort [28] and that we corroborate in our present study. In ALZAN we tracked the interval between blood collection and sample processing, a rarely monitored pre-analytical variable. We could confirm that plasma Aβ levels decreased with the increase of the delay, an observation that was previously made experimentally [40, 41], and that the use of the Aβ42/40 ratio minimized this bias. Another interesting studied ratio is the pTau181/Aβ42 ratio, which has shown excellent performance in detecting AD in CSF, surpassing both the Aβ42/40 ratio and the individual use of pTau181 [42, 43]. pTau181/Aβ42 ratio is seen as a way to account for amyloid (A+), tau (T+) pathologies and neurodegeneration (N+).

In ALZAN, plasma pTau181/Aβ42 and pTau217/Aβ42 ratios result in a significant increase of AUCs for detecting Aβ+, compared to the pTau measurements alone. The interest of computing the pTau181/Aβ42 ratio in blood was already suggested in recent studies [44, 45]. Substituting Aβ42 with the Aβ42/40 ratio did not yield additional benefit. The improvement of AUCs was particularly notable for the pTau181/Aβ42 ratio and less so for pTau217/Aβ42, likely because pTau217 already exhibits excellent standalone performance. The relatively

large size and real-world nature of the ALZAN cohort, with its pre-analytical and clinical variability compared to controlled studies, likely facilitated the demonstration of performance gains for highly effective biomarkers like pTau217. Importantly the superiority of the pTau217/Aβ42 ratio, measured either by immunoassay or mass spectrometry, with regard to amyloidosis detection using PET, was confirmed in the independent ADNI cohort. The pTau181 ratio also helped reduce confounding effects, particularly those related to renal function, which however minimally impacted pTau217. This is also reminiscent of the better performance of mass spectrometry-based methods, which also rely on ratios [46]. The performance improvement going from pTau217 to pTau217/Aβ42 is especially apparent in Apo ε4 non-carriers and individuals with MMSE >25, all of which enhance the potential clinical utility of pTau217/Aβ42. This fits well with findings that Aβ42 performs better in earlier than advanced stages of AD [47, 48].

While the AUC increase between pTau217 and pTau217/Aβ42 was statistically significant, the absolute difference was modest. This raises the question of whether the need to measure two biomarkers, each subject to variability and bias [41], is justified in routine practice. To complete our evaluation of the potential utility of plasma ratios, we analyzed biomarker performance using a 'two-step' workflow with two distinct cutoffs for Aβ+ risk stratification [25]. In memory clinics, such stratification could guide decisions about lumbar punctures or imaging, avoiding redundant tests. We demonstrate that the pTau217/Aβ42 ratio, compared to pTau217 alone, reduces the proportion of patients in the intermediate (uncertain) category by 50% (from 16% to approximately 8%). This improvement is primarily driven by enhanced negative predictive value, consistent with the ratio's superior performance in early cognitive stages.

Our study has some limitations. First, the ALZAN population consists of patients consulting memory clinics who underwent lumbar puncture for CSF biomarker analysis. Extrapolation

to other settings, particularly primary care with likely early AD patients, should be made cautiously. However, it is noteworthy that the performance of the pTau217/Aβ42 ratio was confirmed in the large, independent ADNI cohort, which included both cognitively impaired an addition, in ALZAN the ratios perform equally well or even better in patients with MMSE above 22 (Figure 4). Our study extends a recently published independent work [20]. In this study, the authors confirmed the excellent performance of pTau217, which outperformed pTau181 and the Aβ42/40 ratio. The authors also computed the pTau217/Aβ42 ratio that eventually had higher AUC for Aβ+ than pTau217. However, the focus of their work was not on biomarker ratios, and the authors did not comprehensively evaluate their potential clinical utility as we have done.

In conclusion, this study demonstrated that plasma biomarker ratios, specifically pTau217/Aβ42 and pTau181/Aβ42, significantly enhance the detection of Aβ+ compared to individual biomarkers, particularly in the early stages of AD. The performance of pTau181/Aβ42 was comparable to that of pTau217, while pTau217/Aβ42 enabled a two-fold reduction in the intermediate zone during a two-cutoff stratification of Aβ+ risk. These findings underscore the clinical utility of such ratios in stratifying patients for diagnosis and treatment decisions within memory clinics, potentially reducing unnecessary procedures and improving early-stage detection. However, further validation in diverse clinical settings is necessary to confirm these results.

Materials and Methods

Study population

This study included participants from the ALZAN multicentre prospective cohort (ClinicalTrials.gov Identifier #NCT05427448). Patients were referred while consulting the memory clinics at the Montpellier, Nîmes, or Perpignan hospitals for cognitive complaints, including memory, dysexecutive, or language issues. All participants underwent clinical,

neuropsychological, and biological assessments (see below). Each participant had a lumbar puncture with CSF analysis as part of their routine care. CSF was collected using standardized protocols for collection, centrifugation, and storage [40]. CSF Aβ1-42 and Aβ1-40 (referred to here as Aβ42 and Aβ40) were measured using commercially available (Fujirebio Europe, Ghent, Belgium) on the Lumipulse G1200 analyzer, according to manufacturer protocols. Participants were categorized, as amyloid-positive (Aβ+) or negative (Aβ-), based on their cerebrospinal fluid Aβ42/Aβ40 (ratio below 7%) [31]. Blood samples were collected in EDTA-K2 tubes, the same day as the lumbar puncture and sent to the local clinical laboratory for processing (2000 g × 10 min, RT). The delay between collection and processing in the laboratory (referred to as "blood delay") was recorded. Plasma aliquots were stored at -80°C in low-binding Eppendorf® LoBind microtubes (Eppendorf, ref 022431064, Hamburg, Germany) until testing. eGFR based on creatinine, age, and sex was calculated using the CKD Epidemiology Collaboration (CKD-EPI) equation, revised in 2021 without inclusion of race [49].

Plasma Biomarker Measurements in ALZAN

Plasma aliquots were thawed at +4°C, gently homogenized, and centrifuged for 5 minutes at 2000g before analysis. One aliquot was used for pTau217 measurement using commercial kits on the Lumipulse G1200 as reported [20]. Another aliquot was used for pTau181, Aβ42, Aβ40, and ApoE4 measurement using the NeuroToolKit Elecsys assays on the e402 Cobas analyzer as described [30]. All samples were analyzed by staff who were blinded to the clinical data, and all samples had measurable biomarker values. Limit of detection, intra- and inter-run precision are provided in the supplementary Table 2.

ADNI study population

Two sets of data, originating from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (www.loni.ucla.edu/ADNI), were used after the agreement of the scientific committee. The

first dataset (FNIHBC_BLOOD_BIOMARKER_TRAJECTORIES) relates to the study "Clinical Utility of Blood Biomarker Trajectories" run by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (see acknowledgment). We selected Aβ42, Aβ40 and pTau217 data generated by immunoassays using Lumipulse G® [31] and mass spectrometry using C2N Diagnostics methods [46]. The second dataset (UCBERKELEY_AMY_6MM) provides the PET amyloid status corresponding to the 1179 blood samples from the FNIHBC study. Importantly the mean delay between amyloid PET status and blood collection was 15.6±46.6 days.

Statistical Analyses

Categorical variables were analyzed as percentage and counts (%), continuous variables as mean and standard deviation (M (SD)) and comparisons were made by χ^2 test and t-test or analysis of variance (ANOVA, Kruskal-Wallis test). For all analyses, a two-sided α-level of 0.05 was used for significance testing. Receiving Operator Characteristic (ROC) curves, using amyloid status as a dependent variable, were also used. The corresponding areas under the curve (AUCs) were compared using the Delong method [50]. Missing data were not imputed. Forest plots of associations between biomarkers and demographic/comorbidity features were created using linear regression of z-scores. The coefficients and their 95% confidence intervals are displayed in the plots. All analyses were performed using MedCalc (20·118) and R (R Core Team (2019)) software.

Statements

Acknowledgement

Data collection and sharing for this project was also funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defence award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and

Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. We would like to thank Dr. Susan M. Landau (University of California, Berkeley, USA), for her help in using UCBERKELEY amyloid PET datasets.

Acknowledgement to the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium “Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease” for using their results through ADNI. This study was made possible through a public-private partnership managed by the FNIH and funded by AbbVie Inc., Alzheimer's Association®, Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation, Biogen MA Inc., Janssen Research & Development, LLC, Takeda Pharmaceutical Company Limited. The Project Investigators have not participated in reviewing the data analysis or content of the manuscript.

Funding

Fondation pour la Recherche Médicale (FRM, team Proteinopathies), AXA Mécénat Santé (INTERVAL Project) and Fondation Research Alzheimer (ALZAN projet).

None of the funding bodies had any role in study design, in the collection, analysis, and interpretation of data, in the writing of the report or in the decision to submit the paper for publication.

Authors' contributions

S.L, A.G, F.P, S.J and K.B. take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: S.L, A.G, K.B.
Acquisition of biological data: M.D, M.M.
Analysis, or interpretation of data: All authors.
Drafting of the manuscript: S.L.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: S.L, G.B.
Obtained funding: S.L.
All authors had full access to the data and contributed to revision and editing of the manuscript.

Data availability

Data and informed consent forms are available upon request (CHU Montpellier). Requests will be considered by each study investigator, based on the information provided by the requester, regarding the study and analysis plan. If the use is appropriate, a data sharing agreement will be put in place before distributing a fully de-identified version of the dataset, including the data dictionary used for analysis with individual participant data.

Competing interests

Consultant or Advisory Role: S Lehmann, Advisory Board for Roche diagnostics, Biogen, Lilly, and Fujirabio. A Gabelle, Advisory Board for Biogen, Lilly, and Esai.

Ethical approval

All participants gave written informed consent to be part of the study. The ALZAN study was approved by the “Comité de Protection des Personnes Nord Ouest IV” under # 2022-A00565-38. Clinical trial registration: NCT05427448.

References

1. Jack CR, Jr., Holtzman DM. Biomarker modeling of Alzheimer's disease. *Neuron* **80**, 1347-1358 (2013).

2. Cognat E*, et al.* What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. *BMJ Open* **9**, e026380 (2019).

3. Jack CR, Jr.*, et al.* Revised criteria for the diagnosis and staging of Alzheimer's disease. *Nat Med* **30**, 2121-2124 (2024).

4. Dubois B*, et al.* Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. *JAMA Neurol*, (2024).

5. McKhann GM*, et al.* The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 263-269 (2011).

6. Jack CR, Jr.*, et al.* Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimers Dement* **20**, 5143-5169 (2024).

7. van Dyck CH*, et al.* Lecanemab in Early Alzheimer's Disease. *N Engl J Med* **388**, 9-21 (2023).

8. Sims JR*, et al.* Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *Jama* **330**, 512-527 (2023).

9. Jack CR, Jr., Barrio JR, Kepe V. Cerebral amyloid PET imaging in Alzheimer's disease. *Acta Neuropathol* **126**, 643-657 (2013).

10. Palmqvist S*, et al.* Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. *Neurology* **85**, 1240-1249 (2015).

11. Lehmann S*, et al.* Clarifying the association of CSF Abeta, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease. *Mol Neurodegener* **19**, 66 (2024).

12. Bateman RJ*, et al.* Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* **367**, 795-804 (2012).

13. Hampel H*, et al.* Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat Rev Neurol* **14**, 639-652 (2018).

14. Janelidze S, *et al.* Head-to-Head Comparison of 8 Plasma Amyloid-beta 42/40 Assays in Alzheimer Disease. *JAMA Neurol*, (2021).

15. Mattsson N, *et al.* Plasma tau in Alzheimer disease. *Neurology* **87**, 1827-1835 (2016).

16. Janelidze S, *et al.* Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. *Brain* **146**, 1592-1601 (2023).

17. Barthelemy N, *et al.* Mass spectrometry follow-up of t181, s199, s202, t205, and T217 tau phosphorylation in cerebrospinal fluid from patients revealed a specific Alzheimer's disease pattern. *Alzheimer's & Dementia* **11**, P870 (2015).

18. Barthelemy NR, *et al.* Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. *Alzheimers Res Ther* **12**, 26 (2020).

19. Barthelemy NR, *et al.* A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat Med* **26**, 398-407 (2020).

20. Arranz J, *et al.* Diagnostic performance of plasma pTau(217), pTau(181), Abeta(1-42) and Abeta(1-40) in the LUMIPULSE automated platform for the detection of Alzheimer disease. *Alzheimers Res Ther* **16**, 139 (2024).

21. Ashton NJ, *et al.* Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. *JAMA Neurol* **81**, 255-263 (2024).

22. Janelidze S, *et al.* Plasma Phosphorylated Tau 217 and Abeta42/40 to Predict Early Brain Abeta Accumulation in People Without Cognitive Impairment. *JAMA Neurol* **81**, 947-957 (2024).

23. Lehmann S, *et al.* Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment. *J Neurol Neurosurg Psychiatry* **95**, 1046-1053 (2024).

24. Mielke MM, *et al.* Performance of plasma phosphorylated tau 181 and 217 in the community. *Nat Med*, (2022).

25. Brum WS, *et al.* A two-step workflow based on plasma p-tau217 to screen for amyloid beta positivity with further confirmatory testing only in uncertain cases. *Nat Aging* **3**, 1079-1090 (2023).

26. Verberk IMW, *et al.* Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of

Alzheimer's Blood Biomarkers (SABB) working group. *Alzheimers Dement* **18**, 1484-1497 (2022).

27. Lehmann S*, et al.* Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function. *J Neurol Neurosurg Psychiatry* **94**, 411-419 (2023).

28. Lehmann S*, et al.* Plasma Abeta42/Abeta40 ratio is independent of renal function. *Alzheimers Dement* **19**, 2737-2739 (2023).

29. Brum WS*, et al.* Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Neurol* **81**, 197-200 (2024).

30. Palmqvist S*, et al.* An accurate fully automated panel of plasma biomarkers for Alzheimer's disease. *Alzheimers Dement* **19**, 1204-1215 (2023).

31. Gobom J*, et al.* Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. *Clin Chem Lab Med* **60**, 207-219 (2022).

32. Landau SM*, et al.* Individuals with Alzheimer's disease and low tau burden: Characteristics and implications. *Alzheimers Dement*, (2024).

33. Brickman AM*, et al.* Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. *Alzheimers Dement*, (2021).

34. Janelidze S*, et al.* Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. *Nat Commun* **11**, 1683 (2020).

35. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42/40 ratio in the diagnosis of Alzheimer's Disease. *Alzheimers Res Ther* **11**, 34 (2019).

36. Gervaise-Henry C*, et al.* Cerebrospinal Fluid Abeta42/Abeta40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting. *J Alzheimers Dis* **57**, 437-445 (2017).

37. Dorey A, Perret-Liaudet A, Tholance Y, Fourier A, Quadrio I. Cerebrospinal Fluid Abeta40 Improves the Interpretation of Abeta42 Concentration for Diagnosing Alzheimer's Disease. *Front Neurol* **6**, 247 (2015).

38. Lehmann S*, et al.* Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. *Alzheimers Dement*, (2013).

39. Lehmann S, *et al.* Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. *Alzheimers Res Ther* **12**, 123 (2020).

40. del Campo M, *et al.* Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. *Biomark Med* **6**, 419-430 (2012).

41. Verberk IMW, *et al.* Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. *Alzheimers Dement*, (2021).

42. Leuzy A, *et al.* Robustness of CSF Abeta42/40 and Abeta42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes. *Alzheimers Dement*, (2023).

43. Hansson O, *et al.* CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimers Dement* **14**, 1470-1481 (2018).

44. Chong JR, *et al.* Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. *Alzheimers Dement* **17**, 1649-1662 (2021).

45. Fowler CJ, *et al.* Plasma p-tau181/Abeta(1-42) ratio predicts Abeta-PET status and correlates with CSF-p-tau181/Abeta(1-42) and future cognitive decline. *Alzheimers Dement (Amst)* **14**, e12375 (2022).

46. Meyer MR, *et al.* Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Abeta42/40 ratio to identify presence of brain amyloid. *Alzheimers Dement* **20**, 3179-3192 (2024).

47. Albani D, *et al.* Plasma Abeta42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. *J Alzheimers Dis* **69**, 37-48 (2019).

48. Ashton NJ, *et al.* Differential roles of Abeta42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring. *Nat Med* **28**, 2555-2562 (2022).

49. Inker LA, *et al.* New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. *N Engl J Med* **385**, 1737-1749 (2021).

50. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* **44**, 837-845 (1988).